Childhood acute lymphoblastic leukemia (cALL) is the most common pediatric cancer. It is characterized by bone marrow lymphoid precursors that acquire genetic alterations, resulting in disrupted maturation and uncontrollable proliferation. More than a dozen molecular subtypes of variable severity can be used to classify cALL cases. Modern therapy protocols currently cure 85–90% of cases, but other patients are refractory or will relapse and eventually succumb to their disease. To better understand intratumor heterogeneity in cALL patients, we investigated the nature and extent of transcriptional heterogeneity at the cellular level by sequencing the transcriptomes of 39,375 individual cells in eight patients (six B-ALL and two T-ALL) and three healthy pediatric controls. We observed intra-individual transcriptional clusters in five out of the eight patients. Using pseudotime maturation trajectories of healthy B and T cells, we obtained the predicted developmental state of each leukemia cell and observed distribution shifts within patients. We showed that the predicted developmental states of these cancer cells are inversely correlated with ribosomal protein expression levels, which could be a common contributor to intra-individual heterogeneity in cALL patients.
Childhood acute lymphoblastic leukemia (cALL) is the most frequent pediatric cancer, accounting for ~25% of all pediatric tumors. This cancer is characterized by bone marrow lymphoid precursors that acquire sequential genetic alterations, resulting in disrupted maturation and uncontrollable proliferation. Precursor B cell ALL (B-ALL) represent ~85% of cases and precursor T cell ALL (T-ALL) ~15%, which can be further subdivided into more than a dozen molecular subtypes. The high hyper diploid cases (HHD) and those harboring the t(12;21) [ETV6/RUNX1] rearrangement represent about ~60% of B-ALL cases and are associated with a good prognosis1,2. Other less frequent (<10%) subtypes, such as KMT2A-rearranged, t(9;22) [BCR/ABL1] or T-ALL are associated with less favorable outcomes1,2. Five-year event-free survival rates have seen remarkable progress since the 1960s and are now up to ~85–90% thanks to patient risk stratification and effective treatment combinations3. Despite this therapeutic success refractory and relapsing cALL still represents one of the most frequent cause of death by disease in pediatrics4. This disease is primarily caused by initiating genetic lesions in lymphoid progenitors (chromosomal abnormalities) followed by secondary genetic lesions (copy number alterations, point mutations) leading to leukemogenesis3,5.
Somatic mutations at diagnosis arise in many genes involved in multiple biological pathways such as B cell development (e.g. PAX5, IZKF1), signaling (e.g. RAS, NRAS, CRLF2) epigenetic regulation (e.g. CREBBP, KMT2D) and cell cycling (e.g. CDKN2A)6. This led to the proposition of clonal evolution characterized by a branching model in which leukemic subclones acquire sequential genetic alterations conveying fitness advantages6. In a significant number of relapse cases, ancestral minor subclones present at diagnosis become resistant and positively selected under treatment6,7. Next-generation sequencing (NGS) has recently provided meaningful insights toward the characterization of somatic events providing selective advantages to tumor cells. Mutations in RAS pathway genes have been associated with early relapse and chemoresistance in cALL whereas mutations in the cytosolic 5′-nucleotidase II gene (NT5C2) were shown to be involved in resistance to treatment8,9. A study on the subclonal nature of childhood leukemia revealed that the majority of patients harbor at least one genetic subclone at diagnosis and three quarters of relapse cases were from resistant minor ancestral subclones6. Another study found the presence of at least two distinct genetic subclones in five out of six patients using targeted single-cell DNA sequencing10. In this context, we reported different clonal dynamics between early (during treatment) and late (>36 months after diagnostic) bone marrow relapse events and showed variable clonal origin in late relapse events11.
Genetic alterations of subclones can provide information on the perturbed functions of genes and their corresponding pathways but the transcriptional impacts of these alterations in cALL are unknown as intra-individual transcriptional heterogeneity is not well characterized. Additionally, subclonal epigenetic modifications could cause changes in gene expression that cannot be captured by looking at genetic alterations only. Transcriptional changes at the single cell level can be assessed using recent single cell technologies that enable the transcriptional profiling of thousands of single cells, including droplet-based whole transcriptome profiling (scRNA-seq)12. The prognostic value of scRNA-seq was previously demonstrated in a single cell gene expression study that assessed the transcriptional heterogeneity of patients initially assigned to a unique subtype that were further classified into additional subgroups with distinct survival13. In this study we sought to uncover the extent and nature of transcriptional heterogeneity in cALL patients at diagnosis, identify distinct subpopulations of cancer cells and uncover deregulated genes and pathways. The role of other cellular processes beyond the cell cycle that can lead to intratumoral transcriptional heterogeneity are not well characterized. These intra-individual differences could provide information on the impact of genetic or epigenetic alterations on the expression programs of these cells and help us gain additional knowledge on the mechanisms of disease development.
We generated single cell gene expression data from 39,375 pediatric bone marrow mononuclear cells (BMMCs) from eight cALL patients of common subtypes (4 ETV6-RUNX1, 2 High Hyper Diploid and 2 T-ALL) having >50% blasts and 3 healthy donors (Tables 1 and 2).
We assessed the quality of our data in healthy pediatric BMMCs with available data in healthy adult BMMCs (10X Genomics, Methods). We recovered the expected cell types using known cell surface marker genes (Fig. 1A–D).
In healthy cells, the predicted cell cycle phases showed a higher proportion of cycling cells in B cells and immature hematopoietic than in other cell types (Fig. 1E). By combining healthy pediatric BMMCs with cALL cells (n = 38,922 after quality control), we observed distinct clusters of healthy (PBMMCs) and cancer cells (Fig. 2A).
Between 2 and 60% of cALL cells per sample clustered with healthy pediatric BMMCs of different cell types (Fig. 2C, Supplementary Fig. 1). These cells likely represent non-cancerous cells normally found in samples of variable tumor purity (due to disease severity or technical variability), rather than lineage switching cancer cells or cancer cells having healthy-like transcriptional profiles, which is supported by copy number profiles that are similar to those of PBMMCs (Supplementary Fig. 2). When looking at the predicted cell cycle phases of cALL cells, we observed a continuous spectrum of phases G1 → S → G2/M on the UMAP representation (Fig. 2B). For six out of eight patients, cells were mostly in the G1 phase (Fig. 2D). Many methods can correct for different sources of transcriptional variation14,15, however regressing out the cell cycle phase in our data failed to completely remove this effect as we could still observe clusters of cells in cycling phases on UMAP (Supplementary Fig. 1). Thus, in further analysis, we decided to reduce the expression variability by keeping cancer cells that did not cluster with healthy cells (remaining n = 25,788; ~79.5%) and that were in G1 phase only (remaining n = 16,731; ~51.6%; Fig. 3A).
We looked at the transcriptional profiles of these cancer cells using non-supervised hierarchical clustering of the hundred most variable genes. We observed two distinct clusters of B-ALL and T-ALL cells as shown by the expression of the CD79A/B and CD3D surface markers (Fig. 2E, Supplementary Figure 1). We also noticed transcriptional differences between B-ALL subtypes (e.g. RAG1 over expressed in ETV6-RUNX1 samples) and individuals (e.g. TCL1B over expressed in samples ETV6.RUNX1.3/ETV6.RUNX1.4 and CD1E over expressed in sample PRE-T.1). These transcriptional profiles corroborate expected cell surface marker expression for these types of cells and indicate good quality of the single cell expression data.
Intra-individual transcriptional heterogeneity
We assessed the intra-individual transcriptional heterogeneity by identifying expression profile signatures unique to subsets of cancer cells within a sample. These intra-individual transcriptional differences could highlight deregulated genes in potentially resistant subclones or reveal epigenetic changes driven by subclonal genetic alterations. We applied a strategy that would return the most representative clustering solution over a range of clustering resolutions. Multiple clustering solutions were generated over a range of parameters and pairwise Adjusted Rand Index (ARI) values were computed (Fig. 3B). We retained the clustering solution that had the highest mean ARI and identified at least two clusters in six samples, but no intra-individual transcriptional clusters for samples ETV6.RUNX1.4 and PRE-T.2 (Fig. 3C). Transcriptional differences between subsets of cell within a sample require enough cells (>100) to be properly powered for differential expression analyses16. Thus, we discarded clusters with less than 10% of total cells for samples ETV6.RUNX1.3 and HHD.2 (remaining n = 16,162). This filtering steps resulted in 5 samples with two transcriptional clusters with proportions of cells ranging from ~25 to 50% (Fig. 3D). Repeating the same analysis using cells in S + G2/M phases (n = 9417) identified clusters that were similar to those identified in G1, however differences were observed for some samples which could be due to the lower number of cells in the S + G2/M phases, cell cycle heterogeneity and clustering resolution (Supplementary Figure 3). Identifying transcriptional clusters in each sample individually returned similar results for most samples (Supplementary Figure 4). We then performed intra-individual differential gene expression analyses for the two subsets of cells within these 5 samples. Genes related to B and T cell maturation (e.g. CD37, CD79B, JCHAIN, IGLL1, VPREB3, CD52), ribosomal protein genes (RPS-*, RPL-*) and cancer/stress genes (e.g. PRAME, ARHGDIB, FOS, JUN) (Fig. 3E, Supplementary Table 1) were within the most significantly deregulated genes between clusters in those samples. Gene ontology analyses on the five differential expression gene lists led to a more general understanding of the modulated biological pathways within each sample (Supplementary Table 2). The samples were then clustered based on the top ten most significantly enriched biological pathways. We observed two distinct clusters: one cluster of ETV6-RUNX1 samples showing modulated pathways in B cell activation/differentiation, cell proliferation/death and regulation of expression and metabolic processes and another cluster of HHD and pre-T samples showing modulated pathways in translation initiation and protein synthesis (Fig. 3F). These results demonstrate that we can detect distinct sources of transcriptional variation between subsets of cells within a sample.
Genetic alterations and transcriptional variability
To uncover genetic alterations that could be linked to intra-individual transcriptional heterogeneity, we first looked whether large cluster specific copy number variants (CNVs) could be linked to transcriptional clusters. We generated thirty equal size ‘metacells’ for each cluster to reduce noise and called copy number events using healthy pediatric BMMCs as controls. We recovered most copy number events seen with exome sequencing data and identified cluster specific copy number events (Fig. 4A, Supplementary Figure 5).
We observed cluster specific copy number gains on chromosomes 21 and 22 in sample ETV6.RUNX1.1 and deletions of chromosome 5 and the p arm of chromosome 12 in sample ETV6.RUNX1.2. The chr22 gain and chr5 deletion were found to be subclonal when looking at CNV profiles of individual cells, but we could not confirm the other cluster specific alterations, which could be due to the inherent noise of calling CNVs using single cells (Supplementary Figure 2). Subclonal copy number depth ratios were also seen for some of these alterations using exome data (Supplementary Figure 6). We did not observe large cluster specific copy number events for HHD or pre-T samples. We then looked whether there was a correlation between the presence of genetic subclones and intra-individual transcriptional clusters. We used somatic mutations from matched normal and tumor exome data (Supplementary Table 3) and found no major differences in both the number of mutations and genomic locations between samples (except for sample ETV6.RUNX1.1 that had less mutations) (Fig. 4B,C). We identified known cALL mutations in signaling proto-oncogenes (ABL1, ROS1, NOTCH1), cell cycle/epigenetic regulators (CREBBP, CDKN2A) and noticed few overlapping non-synonymous exonic mutations between samples (Fig. 4D). We used all sufficiently covered (>100×) somatic mutations to generate genetic evolution models and at least one minor genetic subclone was predicted for each sample, with ETV6.RUNX1.2 having two minor subclones (Supplementary Figure 7). We therefore did not observe a correlation between the presence of genetic subclones and observed intra-individual transcriptional heterogeneity, however minor subclones were at the lower end of the allele frequency spectrum and could reflect the neutral evolution frequency tail in some cases17. Finally, we looked at somatic mutations at the single cell level using all somatic mutations and retrieved allele calls of individual cells using single cell RNA-seq read alignment files. Around 25% of mutations (n = 668) were covered in at least one cell and ~6.7% (n = 185) of them had at least one cell having the mutated allele (Fig. 4E). A Fisher’s exact test was run on mutations having at least >0.1% of cells per sample with the mutated allele (n = 31) to identify overrepresented mutations in intra-individual transcriptional clusters. We found somatic mutations in three genes with p-values < 0.1 for samples ETV6.RUNX1.2 and PRE-T.2 (intron of C20orf194, 3′ UTR of SH3 domain containing gene SH3D21 and exon of pyridoxal kinase gene PDXK), indicating a slight enrichment of the mutated allele in a transcriptional cluster (Supplementary Table 4). Overall very few somatic mutations were fulfilling the criteria for statistical testing and many mutations had a low number of observations contributing to underinflation of p-values and non-significance of all mutations after multiple testing correction (Fig. 4F, Supplementary Table 4). Thus, it is still possible that other subclonal somatic mutations could be enriched in specific transcriptional clusters but were not possible to detect using this approach. Overall these results suggest that there is some limited evidence linking genetic alterations detected from bulk exome data to intra-individual transcriptional heterogeneity in these samples.
Developmental states and ribosomal protein gene expression
To address whether the observed intra-individual transcriptional variability could be linked to the maturation and differentiation states of the cancer cells, we implemented two developmental state classifiers based on the expression profiles of healthy B and T cells. We assigned pseudotime values of 0 to 1 along the maturation spectrum from stem-like to mature developmental states (Fig. 5A).
The performances of the classifiers were assessed on healthy cells using cross-validation and showed good predictive performance using average Root Mean Squared Error (RMSE) (Fig. 5B). Final classifiers were trained on all healthy B and T cells and then used to obtain the predicted developmental states of every cancer cell. We observed statistically significant shifts in developmental pseudotime distributions within samples (Fig. 5C). The most significant shifts were found within HHD and PRE-T samples, while less pronounced shifts were observed within ETV6-RUNX1 samples. These findings correlate with differential expression results that revealed modulated expression of ribosomal protein genes in HHD and PRE-T samples (Supplementary Table 1). An inverse relationship between maturation states of normal hematopoietic cells and ribosomal protein (RP) expression levels was previously reported in a zebrafish single cell RNA-seq study18. We observed the same relationship for cALL cancer cells in all samples exhibiting intra-individual transcriptional clusters where subsets of cells with higher pseudotime had lower ribosomal protein expression levels (Fig. 5D). This trend was clearer in samples having strong (e.g. HHD.1) vs weak (e.g. ETV6.RUNX1.2) shifts in pseudotime (Fig. 5E). Ordering cells by RP expression revealed a gradient of expression that was correlated to clusters having similar behavior (Fig. 5F). These findings suggest that developmental states and RP expression could contribute to the intra-individual transcriptional heterogeneity observed in some cALL patients.
We applied a single cell expression strategy to uncover major sources of intra-individual transcriptional heterogeneity in childhood ALL. To our knowledge this is the first study on intra-individual transcriptional heterogeneity in cALL patients using single cell gene expression. Our study found two notable patterns at diagnosis: first, we found transcriptional heterogeneity associated to the predicted developmental state of leukemia cells which was inversely correlated with the expression of ribosomal protein genes. This observation was more obvious in HHD and pre-T samples and less so in ETV6-RUNX1 samples, indicating possible subtype specificity. The disrupted products of the fusion between the ETV6 and RUNX1 transcription factors, involved in B cell maturation, could result in an overall lower maturation potential of the leukemia cells. Second, we observed transcriptional heterogeneity linked to gene expression and metabolic regulation, B cell activation and cell proliferation/death in ETV6-RUNX1 samples. We found significant joint over expression of the JUN and FOS proto oncogenes in a cluster of cells for sample ETV6.RUNX1.2, suggesting deregulation in stress/cancer genes.
To further understand transcriptional variability within samples, we sought to determine if genetic alterations could explain these intra-individual transcriptional clusters. We called copy number variants (CNVs) in each sample to detect events present specific to transcriptional clusters and found a few large gain and loss events in subsets of cells of ETV6-RUNX1 samples. Given the high number of genes in these regions, the transcriptional impacts of these copy number alterations remain unknown. We found no correlation between the number of predicted genetic subclones in each sample and the presence of intra-individual transcriptional clusters. All samples were predicted to have two or more genetic subclones but not all samples were found to have intra-individual transcriptional clusters, which could be explained in part by our single cell clustering procedure retaining the ‘most representative’ solution and not returning all possible transcriptional clusters. Another explanation could be false positive predictions of genetic subclones triggered by the density of mutations found at the lower allele frequency spectrum and arising from neutral tumor evolution. The low number of somatic mutations in pediatric cancers19, coupled with limited coverage of the exome (versus whole-genome) and lower sequencing depth (~200–300X) compared to targeted sequencing (~1000–1500X) could have contributed to the problem. We then looked for somatic mutation allele enrichment in specific transcriptional clusters by assigning allele calls to each cell using the single cell RNA-seq read alignment files. Since very few mutations had enough coverage and alternate allele calls to be tested for statistical significance, we failed to report strong evidence of mutant allele enrichment. These results could be explained by the limited expression levels of genes in each cell and the uneven coverage over genes inherent to the 3′ single cell library protocol. Assessing DNA and RNA simultaneously in the same cell is a strategy that could reduce the limitations mentioned above; technology to do this exists but was initially limited to a few hundred cells20. Newer methods can amplify targeted genomic regions21 or transcripts of interest22,23 in thousands of cells to generate both the transcriptional and mutational profiles of individual cells. Additionally, an analytical approach that combines both single cell RNA and DNA generated from the same system, but not the same cells, has been developed to jointly analyze genetic and transcriptional clonality and could be useful to apply in subsequent studies24. Taken together we found some evidence, although limited, of subclonal genetic alterations that were linked to intra-individual transcriptional heterogeneity in cALL samples. It is likely that subclonal genetic events altering expression could be more easily identifiable in samples where the main source of transcriptional heterogeneity is not related to the predicted developmental state.
Questions remain about the clinical significance of intra-individual transcriptional heterogeneity in cALL. It is unclear whether subsets of cells at various developmental stages or with variable levels of maturation potential have any fitness advantages during treatment. A previous study exploring the relapse potential of cALL patients at diagnosis projected individual cancer cells to their closest B cell maturation state using mass cytometry and found no correlation between the fraction of cells in a given state and relapse potential25. Subsets of cells having deregulated expression of oncogenes (e.g. sample ETV6.RUNX1.2) or genes involved in treatment resistance could be more susceptible to clonal selection. Although no patients in our study have relapsed, future single cell studies using matched diagnosis/relapse should provide valuable information on clonal dynamics. Single cell expression data of matched cells should help identify genes and cell surface markers that gain or lose expression in resistant cells and provide insights to guide clinical interventions.
Study subjects were diagnosed in the Division of Hematology-Oncology at the Sainte-Justine Hospital (Montreal, Canada) and part of the Quebec childhood ALL cohort (QcALL)26. Our study cohort consisted of 6 B-ALL and of 2 T-ALL patients (8 males) with a mean age at diagnosis of 5.8 years and a mean blast percentage of 82% (Table 1). All patients were treated under DFCI protocols. Control subjects were patients for whom the diagnosis of ALL was not confirmed after bone marrow puncture (3 males) and with a mean age of 2.7 years (Table 1). Tumoral DNA specimens were collected from bone marrow mononuclear cells (BMMCs) at initial diagnosis and paired normal DNA specimens were collected from peripheral blood or bone marrow samples without blast cells. All samples were isolated using a Ficoll-Paque gradient fragmentation, washed in PBS and DNA was extracted using the Gentra Puregene Blood Kit from QIAGEN according to manufacturer protocol. For single cells, bone marrow mononuclear cells were cryopreserved in FBS with 10% DMSO. The Sainte-Justine Institutional Review Board approved the research protocols and informed consents were obtained from all participating individuals and/or their parents. All experiments have been carried out in accordance with relevant guidelines and regulations.
Single cell RNA sequencing and analyses
Thawed BMMCs were loaded onto the 10X Genomics Chromium single cell platform (v2 chemistry) at McGill University and Genome Quebec Innovation Center. We aimed for 3,000 cells per sample and targeted 100,000 reads per cell by sequencing each sample on one lane of an Illumina HiSeq 4000 high-throughput sequencer (26v98 b.p. paired-end sequencing) (Table 2).
Sequencing reads were processed using the Cell Ranger v2.1.0 pipeline on Ensembl GRCh38.8412. BMMCs from three healthy pediatric controls and two publicly available healthy adult control samples (www.10Xgenomics.com) were analyzed jointly using the canonical correlation analysis (CCA) in Seurat v2.3.215. Genes expressed in at least 5 cells, cells having at least 200 genes expressed and cells having less than 8% mitochondrial reads were retained for the analysis. Expression estimates of the genes were regressed out for number of unique molecular identifiers (nUMI), percentage of mitochondrial reads and the S and G2/M cell cycle scores. The thousand most variable genes were selected for each sample and pooled to create a unique list of genes being highly variable in at least two samples (n = 883). These genes were kept for the CCA and the top ten canonical correlation vectors were used as input for UMAP v0.2.327. Cell types were identified using the expression of known cell surface marker genes (CD34/CD34+, CD79A/B cells, MS4A1/CD20+ B cells, CST3/monocytes, SPN + KIT/immature hematopoietic, HBA1/erythrocytes, CD3D/T cells, NKG7/NK cells, MZB1/BCMA). A second analysis was done on cells of three healthy pediatric controls and eight cancer samples. The same cell and gene filters as described above were applied and a Seurat object was created by iteratively merging each dataset. A principal component analysis (PCA) was run on the most variable genes (n = 468) and the top twenty principal components were used as input for both UMAP and cluster identification using Louvain’s algorithm28 with a resolution of 0.1. Cells from cancer samples that did not cluster with control cell clusters and those that were in the G1 cell cycle phase were retained for downstream analyses. The most variable genes were identified in these filtered cells (n = 560) and used as input for both PCA and UMAP. The most representative clustering solution was obtained by finding clusters using resolutions of 0.1 to 3.0 with a step of 0.1. For each of these 30 solutions, we computed all pairwise Adjusted Rand Index (ARI) values and retained the clustering solution with the highest ARI mean (optimal resolution = 1.3). Clusters containing less than 10% of cells in a sample were discarded for statistical reasons. Intra-individual differential gene expression analyses were done using the MAST test29 (Supplementary Table 1). Gene ontology analyses were done using goseq v1.3.030 on the top hundred differentially expressed genes ranked by adjusted p-value. Single cell allele calls of somatic mutations derived from exome data were obtained using vartrix v1.1.031. Copy number profiles of intra-individual transcriptional clusters were obtained by generating thirty equal-sized metacells (sum of raw expression counts of single cells) per cluster that were used as input to infercnv v.0.99.432. Metacells of healthy pediatric BMMCs were used as control.
Exome sequencing and analyses
Exome sequencing and analyses were performed as previously described33; whole exomes were captured using Agilent’s SureSelect XT Clinical Research Exome kit per manufacturer’s protocol and librairies were sequenced on Illumina high throughput sequencers (HiSeq 2500 or 4000 in paired-end 2 × 75b.p. or 2 × 100b.p.) targeting mean coverage of 300X for tumor and 100X for normal. Raw reads were aligned to the hg19 genome reference using bwa v0.7.734, duplicates were marked using Picard v1.107 (http://broadinstitute.github.io/picard/) and indels realigned and bases recalibrated using GATK v3.3.035. Somatic mutations of matched tumor/normal were obtained using mutect v1.1.636, filtered for the PASS flag and variant allele frequency >0.05 (n = 2748, Supplementary Table 3). Variants were lifted over using vcf-liftover (https://github.com/liqg/vcf-liftover) for use with single cell RNA-seq data (hg19 → GRCh38, n = 2731/2748, 99.4%). Mutations with high coverage (>100X) were used as input to sciClone v1.1.037 and clonEvol v0.99.1138 to generate clonal evolution models. Copy number calls were obtained using sequenza v2.1.039.
Developmental state classifiers and ribosomal protein expression
UMAP coordinates of healthy BMMCs corresponding to the developmental spectrum of B cells (CD34+, B cells and CD20+ B cells) and T cells (CD34+, immature hematopoietic, T cells) were extracted for input to loess fits. Cells were projected onto the fit line at the closest distance. Outlier cells with distances of more than three standard deviations from the mean were discarded. Cell distances along the fit line were calculated, scaled between 0 and 1 and set as the developmental state pseudotime. Normalized and scaled expression values of the most variable genes determined in the Seurat CCA were extracted and used as input for one-layer fifteen nodes neural networks using the R package nnet v7.3–12. Classifier performances on control cells were assessed using cross-validation of a hundred 70/30 splits and mean RMSE values were computed. Final classifiers were trained on all healthy cells and used to predict the developmental pseudotime of each leukemia cell. Ribosomal protein (RP) expression per cell was defined as the ratio of raw reads mapped to ribosomal protein genes (n = 97, Supplementary Table 5) divided by the total number of raw reads per cell.
Single cell RNA-seq data are available in GEO under GSE132509. Code are available on github (https://github.com/sinnettlab/childhood_leukemia_single_cell_expression).
Mullighan, C. G. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest 122, 3407–3415, https://doi.org/10.1172/JCI61203 (2012).
Woo, J. S., Alberti, M. O. & Tirado, C. A. Childhood B-acute lymphoblastic leukemia: a genetic update. Exp Hematol Oncol 3, 16, https://doi.org/10.1186/2162-3619-3-16 (2014).
Hunger, S. P. & Mullighan, C. G. Acute Lymphoblastic Leukemia in Children. N Engl J Med 373, 1541–1552, https://doi.org/10.1056/NEJMra1400972 (2015).
Pui, C. H., Mullighan, C. G., Evans, W. E. & Relling, M. V. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 120, 1165–1174, https://doi.org/10.1182/blood-2012-05-378943 (2012).
Iacobucci, I. & Mullighan, C. G. Genetic basis of acute lymphoblastic leukemia. Journal of Clinical Oncology 35, 975 (2017).
Ma, X. et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nature communications 6, 6604, https://doi.org/10.1038/ncomms7604 (2015).
Ferrando, A. A. & López-Otín, C. Clonal evolution in leukemia. Nature medicine 23, 1135 (2017).
Irving, J. et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 124, 3420–3430, https://doi.org/10.1182/blood-2014-04-531871 (2014).
Tzoneva, G. et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med 19, 368–371, https://doi.org/10.1038/nm.3078 (2013).
Gawad, C., Koh, W. & Quake, S. R. Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proc Natl Acad Sci USA 111, 17947–17952, https://doi.org/10.1073/pnas.1420822111 (2014).
Spinella, J. F. et al. Mutational dynamics of early and late relapsed childhood ALL: rapid clonal expansion and long-term dormancy. Blood Adv 2, 177–188, https://doi.org/10.1182/bloodadvances.2017011510 (2018).
Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nature communications 8, 14049, https://doi.org/10.1038/ncomms14049 (2017).
Li, H. et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat Genet, https://doi.org/10.1038/ng.3818 (2017).
Buettner, F., Pratanwanich, N., McCarthy, D. J., Marioni, J. C. & Stegle, O. f-scLVM: scalable and versatile factor analysis for single-cell RNA-seq. Genome biology 18, 212 (2017).
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nature biotechnology 36, 411 (2018).
Wang, T., Li, B., Nelson, C. E. & Nabavi, S. Comparative analysis of differential gene expression analysis tools for single-cell RNA sequencing data. BMC Bioinformatics 20, 40, https://doi.org/10.1186/s12859-019-2599-6 (2019).
Graham, T. A. & Sottoriva, A. Measuring cancer evolution from the genome. The Journal of pathology 241, 183–191 (2017).
Athanasiadis, E. I. et al. Single-cell RNA-sequencing uncovers transcriptional states and fate decisions in haematopoiesis. Nature communications 8, 2045 (2017).
Grobner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321–327, https://doi.org/10.1038/nature25480 (2018).
Macaulay, I. C. et al. G&T-seq: parallel sequencing of single-cell genomes and transcriptomes. Nature methods 12, 519–522 (2015).
Rodriguez-Meira, A. et al. Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing. Molecular cell 73, 1292–1305. e1298 (2019).
van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265–1281. e1224 (2019).
Nam, A. S. et al. Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature 571, 355–360 (2019).
Campbell, K. R. et al. clonealign: statistical integration of independent single-cell RNA and DNA sequencing data from human cancers. Genome biology 20, 54 (2019).
Good, Z. et al. Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. Nature medicine 24, 474 (2018).
Healy, J. et al. Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia. Blood 109, 683–692 (2007).
McInnes, L., Healy, J. & Melville, J. Umap: Uniform manifold approximation and projection for dimension reduction. arXiv preprint arXiv:1802.03426 (2018).
Blondel, V. D., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. Fast unfolding of communities in large networks. Journal of statistical mechanics: theory and experiment 2008, P10008 (2008).
Finak, G. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol 16, 278, https://doi.org/10.1186/s13059-015-0844-5 (2015).
Young, M. D., Wakefield, M. J., Smyth, G. K. & Oshlack, A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol 11, R14, https://doi.org/10.1186/gb-2010-11-2-r14 (2010).
Petti, A. A. et al. Mutation detection in thousands of acute myeloid leukemia cells using single cell RNA-sequencing. BioRxiv, 434746 (2018).
Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401, https://doi.org/10.1126/science.1254257 (2014).
Khater, F. et al. Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers. JAMA network open 2, e192906–e192906 (2019).
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. bioinformatics 25, 1754–1760 (2009).
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome research 20, 1297–1303 (2010).
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature biotechnology 31, 213 (2013).
Miller, C. A. et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS computational biology 10, e1003665 (2014).
Dang, H. et al. ClonEvol: clonal ordering and visualization in cancer sequencing. Annals of oncology 28, 3076–3082 (2017).
Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Annals of Oncology 26, 64–70 (2014).
The authors are indebted to the patients and their parents for participating in this study. Patient tissue samples were provided by the Sainte-Justine UHC Pediatric Cancer Biobank. Computations were run on the Cedar cluster managed by Compute Canada. This work was supported by grants from the FIT program and the Charles-Bruneau Foundation. M.C. received a PhD studentship from the FRQS. D.S. holds the research chair Francois-Karl-Viau in pediatric oncogenomics. G.B. obtained funding from CIHR grant 245250 and is funded by the FRQS.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Caron, M., St-Onge, P., Sontag, T. et al. Single-cell analysis of childhood leukemia reveals a link between developmental states and ribosomal protein expression as a source of intra-individual heterogeneity. Sci Rep 10, 8079 (2020). https://doi.org/10.1038/s41598-020-64929-x
This article is cited by
ASGARD is A Single-cell Guided Pipeline to Aid Repurposing of Drugs
Nature Communications (2023)
Single-cell technologies uncover intra-tumor heterogeneity in childhood cancers
Seminars in Immunopathology (2023)
The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective
Nature Communications (2022)
Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis
Nature Cell Biology (2022)
Integrated multi-omic characterization of congenital heart disease
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.